Analyst
Goldman Sachs
Equibles does not estimate personal net worth.
Shams Srinivasan is recorded as Analyst at Goldman Sachs. Shams Srinivasan has spoken on 2 earnings calls across 2 companies, most recently for Cipla Limited on October 27, 2026. Those appearances were for Cipla Limited and Syngene International Limited. The companies whose calls Shams Srinivasan spoke on are classified in the Healthcare sector.
“Just looking at the India business prescription growth, the branded prescription growth, 15%, if I were to kind of leave out, and maybe I'm being selective, to leave out the anti-diabetes portfolio or including conglutide, we have seen slower growth than market.”
“Just between January and now we are reporting in April, you know, we had cut our EBITDA myosin guidance for the full year to 22-23 percent, and we delivered 25.”
Goldman Sachs
Analyst
Transcript header (unverified)
Cipla Limited
Drug Manufacturers - Specialty & Generic · Healthcare
Syngene International Limited
Diagnostics & Research · Healthcare
Earnings Call for the Quarter Ended September 30, 2026
Cipla Limited
Earnings Call
Syngene International Limited
